Navigation Links
Delcath to Present at Upcoming Investor Conferences
Date:3/2/2011

NEW YORK, March 2, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that executive management will present an overview of the Company's business strategy and recent corporate developments at the following investor conferences:

  • The Cowen and Company Healthcare Conference in Boston.  Mr. Eamonn Hobbs, Chief Executive Officer, and Mr. David McDonald, Chief Financial Officer, are scheduled to present an overview of the Company on Tuesday, March 8, 2011 at 10:15 a.m. ET.
  • ROTH Capital Annual OC Growth Stock Conference in Laguna Niguel, California.  Mr. Hobbs is scheduled to present an overview of the Company on Monday, March 14, 2011 at 1:30 p.m. PT.

  • Attendance at each of these conferences is by invitation only. Delcath will offer live and audio webcasts of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentations will be available for 90 days, also at www.delcath.com.

    About Delcath SystemsDelcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at

    SOURCE Delcath Systems, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Delcath Systems Receives Refusal to File Letter From FDA
    2. Delcath Achieves ISO 13485 Certification
    3. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
    4. Delcath Systems Announces Third Quarter Progress Report Conference Call
    5. Delcath Strengthens Research and Development Team with Key Appointments
    6. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
    7. Delcath to Present at the William Blair Emerging Growth Stock Conference
    8. Delcath to Present at the JMP Securities Healthcare Conference
    9. Delcath Systems Announces Completion of Common Stock Offering
    10. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
    11. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
    (Date:8/31/2015)...  DICOM Grid,  the #1 medical image exchange ... as a semifinalist for a Minnie award for ... are sponsored by Auntminnie.com, a comprehensive community website ... imaging industry.  Since 1999, the "Minnies" have provided ... contributions of their peers. Nominations are made by ...
    (Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
    Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
    (Date:9/1/2015)... , ... September 01, 2015 , ... Royal River Natural ... study that followed men and women for 19 years and found that, among those ... not take multivitamins. , The report is part of the September 2015 issue of ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... D.O., has joined its medical management team as an Associate Medical Director. ... sizes and types in the U.S. and abroad. , Dr. Nelson has ...
    (Date:9/1/2015)... , ... September 01, 2015 , ... Two of Washington ... cultural relations through food and dining. , Recently named “the next big thing” ... Diotaiuti are known for telling the whole story behind food and reclaiming culinary traditions ...
    (Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, tax, ... named a “Best of the Best” firm in the U.S., as well as being ... of the Best” in the U.S., selected exclusively on performance in specific areas of ...
    (Date:9/1/2015)... , ... September 01, 2015 , ... ... Kit is now available. With the Connectivity Kit, EasySampler data is ... jacketed lab reactor control experiment, on a touchscreen platform. , EasySampler fully ...
    Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
    ... Northeast, and boys are at higher risk than girls, study ... sweeping government study of childhood cancers has found numerous differences ... and where he or she lives in the United States. ... cancers, the researchers found, and youngsters in the Northeast were ...
    ... June 2 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) ... its lead anticancer agent Cloretazine(R) (VNP40101M) in,combination with cytarabine ... had been presented at the 44th Annual Meeting of,the ... The Phase III trial started in March 2005 ...
    ... (ASCO) ... Annual Meeting -, IRVINE, Calif., June 2 ... an analysis from the,Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The results,suggest ... reduction in the risk of death in newly diagnosed,patients with metastatic osteosarcoma, ...
    ... Marketing and, Communications Professionals for Inspiring Tales of Patient and ... ... EL SEGUNDO, Calif., June 2 DaVita Inc., a leading,provider ... failure (CKD), today announced that the company,s internal,publication, DaVita Magazine: Stories ...
    ... BETHESDA, Md., June 2 /Xinhua-PRNewswire/ -- Chindex ... Western healthcare,services and products in the People,s ... division, United Family Healthcare (UFH), responded to,the ... personnel,and other in- kind donations., Roberta ...
    ... the overall rate of high school baseball-related injuries has ... injuries that occur has increased, according to a new ... Research and Policy (CIRP) of The Research Institute at ... estimated 132,000 high school baseball-related injuries occurred with an ...
    Cached Medicine News:Health News:U.S. Childhood Cancers Vary by Sex, Region 2Health News:U.S. Childhood Cancers Vary by Sex, Region 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 2Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 3Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 5Health News:DaVita Magazine Takes Home Two Prestigious Hermes Creative Awards 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 3Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 4Health News:Injuries to high school baseball players becoming more serious 2
    The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
    ... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
    ... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
    ... The 45° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
    Medicine Products: